Forest Labs receives warning from FDA on Bystolic marketing

WASHINGTON Forest Laboratories has received a warning from the Food and Drug Administration concerning its hypertension drug Bystolic, alleging that it marketed the drug without properly informing doctors of its risks, the FDA said in a letter to the company Monday.

Forest placed an advertisement in several medical journals implying the drug was superior to rival products despite the lack of evidence to back the claim.

The letter stated that the drug has been linked to serious side effects, including chest pain and heart failure.